Kornimate/medical-research-clean huggingface dataset:
observational registry study of quality of life when treating btcp with abstral

Conditions: Quality of Life; Breakthrough Cancer Pain

Summary: this observational registry study is designed to collect self-reported transmucosal immediate release fentanyl (tirf) risk evaluation and mitigation strategy (rems) access program-enrolled patient experience with breakthrough cancer pain (btcp) as a result of treatment with abstral® through the use of quality of life and pain measurement tools administered via questionnaire.

this is a post-marketing, single arm, open label multicenter trial to assess abstral (fentanyl) sublingual tablets for breakthrough cancer pain (btcp) in opioid-tolerant cancer patients. * prior to study enrollment, patient enrollment in the tirf rems access program must be confirmed. * eligible patients will sign written informed consent. patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may use a proxy caregiver to assist in the completion of the study questionnaires. * day 0, study site must enroll patient by completing a patient demographic profile (de-identified). * day 0, patient will be instructed how to use the questionnaires. * day 0, patient will complete the baseline questionnaire before leaving the physician office. * on study days 14, 21, and 28 (±3 days) patient questionnaire will be completed by patient (or caregiver proxy) via secure online data entry portal. * for patients completing paper questionnaires, within 1 month of day 28, patient will return completed questionnaires via mail, fax or hand carried to the study site coordinator for processing. * patient will be considered to have completed the study successfully once all completed questionnaires have been received by the cro within appropriate time limits.

Eligibility criteria:
inclusion criteria: * all patients 18 years of age and older with breakthrough cancer pain who are registered in the transmucosal immediate release fentanyl (tirf) risk evaluation and mitigation strategy (rems) access program and receiving abstral® under the direction of a tirf rems access program-registered physician are eligible for the study. patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may also use a proxy caregiver to assist in the completion of the study questionnaires. exclusion criteria: * no patient can be enrolled who has not been prescribed abstral for btcp in compliance with transmucosal immediate release fentanyl (tirf) risk evaluation and mitigation strategy (rems) access program guidelines. no patient may be enrolled who has a contraindication to receiving abstral or who is pregnant.

Keywords: breakthrough cancer pain diary quality of life abstral btcp
fluid challenge and plasma volume, during surgery

Conditions: Colorectal Cancer; Urologic Cancer; Gynecologic Cancer; Colorectal Disorders; Benign Neoplasm

Summary: a short bolus infusion of fluid, called "fluid challenge" is commonly recommended for fluid treatment during longer surgery. however a prolonged increase of the blood volume is a prerequisite to recommend the technique. the purpose with the study is to examine the plasma expanding effect of three different fluid challenge strategies (acetated ringers 4 ml/kg body weight, albumin 5% 4 ml/kg body weight or albumin 20% 1 ml/kg body weight), using hemoglobin as a dilution indicator.

60 patients scheduled for laparoscopic abdominal surgery, with a duration exceeding 90 minutes will be included in the study. these are randomized to three different groups (20 in each groups): the first group of patients will receive boluses of acetated ringers 4 ml/kg body weight. the second albumin 4 ml/kg body weight and the third group albumin 20% 1 ml/kg body weight. hemoglobin, albumin and colloid osmotic pressure (cop) is sampled the day before surgery and in the morning directly prior to the anesthesia. bioimpedance, urine osmolality and urine-creatinin are also measured. after induction of surgery a cardio q probe is inserted threw the nose into the esophagus, for circulatory measurements. initial/baseline blood samples are taken after insufflation of carbon dioxide to the abdomen. before every bolus of fluid and 5, (10), 15, 20, 30, 40, (50) and (60) minutes new blood samples are taken for determination of hemoglobin, albumin and cop. artery blood gases are sampled 15 minutes after every infusion or depending on the clinical need.

Eligibility criteria:
inclusion criteria: * written consent to participate in the study * for women: relevant contraceptive, menopausal or a negative pregnancy test. * asa category i to iii * laparoscopic abdominal surgery, with a duration of at least 90 minutes. * 18 to 80 years exclusion criteria: * patients with known cardiac failure * \ 80 years * known allergy to albumin * extracellular hyperhydration or hypervolemia * kidney failure * pregnancy or planned pregnancy

Keywords: laparoscopic surgery, fluid therapy, plasma volume
immunophenotypage of rif and rm patients and intrauterine administration of pbmc

Conditions: Infertility, Female

Summary: the purpose of this study is to identify a systemic immunological profile specific to patients with recurrent implantation failures (rif) or miscarriages (rm) through blood immunophenotyping on the day of ovulation. this study also aims to determine whether the intrauterine administration of 5 million peripheral blood monocluear cells increases implantation and pregnancy rates in patients with rif and decreases the risk of miscarriages in patients with rm, compared to what has already been published in the scientific literature


Eligibility criteria:
inclusion criteria: * all women aged 18 and over undergoing an ivf cycle with her partner's sperm at the fertilys fertility center, without a rif status, agreeing to participate in the study and having signed the consent form to participate in the study. * all women aged 18 and over undergoing an ivf cycle with her partner's sperm at the fertilys fertility center, with a rif or rm status, agreeing to participate in the study and having signed the consent form to participate in the study. exclusion criteria: * women who need a gametes donor (eggs and / or sperm). * women undergoing an ivf cycle with frozen sperm. * women with autoimmune disease. * women with diabetes. * women with a history of chemotherapy treatment.
telbivudine versus lamivudine in adults with decompensated chronic hepatitis b and evidence of cirrhosis

Conditions: Hepatitis; Hepatitis B, Chronic; Cirrhosis

Summary: this research study was conducted to compare the safety and effectiveness of the investigational medication, ldt (telbivudine) versus lamivudine, a drug currently approved by the us, european and asian health authorities for the treatment of hepatitis b infection. the results for patients taking ldt will be compared to results for patients taking lamivudine.

multicenter, multinational, randomized, double-blind study designed to compare the safety and efficacy of telbivudine (600 mg/day) versus lamivudine (100 mg/day) for 104 weeks in adults with decompensated chronic hepatitis b and evidence of cirrhosis. patients were pre-stratified by screening child-turcotte-pugh score (ctp score \ 1.0 x uln) to help assure similar degrees of hepatic insufficiency and liver inflammation on both treatment arms. after 104 weeks of treatment, participants were followed-up with for an additional 16 weeks.

Eligibility criteria:
inclusion criteria: * documented decompensated chronic hepatitis b defined by all of the following: 1. clinical history compatible with decompensated chronic hepatitis b related cirrhosis; 2. child-turcotte-pugh score \> 7 points. * evidence of hepatic cirrhosis or portal hypertension. other protocol-defined inclusion criteria may apply. exclusion criteria: * patient is pregnant or breastfeeding. * patient is coinfected with hepatitis c virus (hcv), hepatitis d virus (hdv), or human immunodeficiency virus (hiv). * patient previously received lamivudine, adefovir, or an investigational anti-hepatitis b virus (hbv) nucleoside or nucleotide analog at any time * patient has received interferon or other immunomodulatory treatment for hbv infection in the 12 months before screening for this study. other protocol-defined exclusion criteria may apply.
trial of pancreatic enzyme supplements (pancrelipase) for treating pain in patients with chronic pancreatitis

Conditions: Pancreatitis

Summary: the study purpose is to characterize the effect of pancreatic enzyme supplementation on chronic pancreatitis type pain.

study type: interventional, randomized, double-blind, placebo-controlled, crossover design, efficacy study intervention arm: pancreatic enzyme replacement (pancrelipase) with meals and snacks daily, for 4 weeks. placebo arm: lactose placebo tablets with meals and snacks, for 4 weeks. washout phase: weeks 4 to 6, there will be cessation of placebo or pancrelipase use. crossover phase: weeks 6 to 10, initial placebo arm receives pancrelipase, pancrelipase arm receives placebo surveys - izbicki score and panqoli assessment occur at week 0, 4, 6, and 10. narcotic and non-narcotic usage will also be noted at these intervals. patient will also report the tobacco and alcohol use.

Eligibility criteria:
inclusion criteria: * diagnosis of chronic pancreatitis based on chronic pancreatitis-type pain \> 6 months leading to impaired quality of life and at least 1 of the following (27): * confirmed diagnosis of hereditary pancreatitis (prss1 gene mutation) * history of recurrent acute pancreatitis (\>1 documented episode of characteristic abdominal pain associated with diagnostic imaging and/or elevated serum amylase or lipase \> 3 times upper limit of normal). * pancreatic calcifications on ct scan * at least 2 of the following: * endoscopic ultrasound (eus) with = or \> 4 criteria for chronic pancreatitis (hyperechoic foci, strands, or ducts, lobulation, irregular duct margin, visible side - branches, calcifications, cysts, ductal dilatation) (28) * ductal (changes in side branch morphology) or parenchymal (loss of t1 signal intensity) abnormalities on secretin enhanced magnetic resonance cholangiopancreatography (mrcp) * abnormal endoscopic pancreatic secretory function tests (hco3 \<= 75mmol/l at 30 or 45 minutes or \<= 80mmol/l at 1 hour * subjects are capable of informed consent exclusion criteria: * pregnancy * lactation * active acute pancreatitis or an episode of acute pancreatitis within 2 months of presentation for evaluation * pancreatic cancer
comparison between mcgrath and macintosh laryngoscopes for dlt intubation in thoracic surgery patients.

Conditions: Thoracic Diseases; Thoracic Neoplasms; Thoracic Empyema

Summary: the goal of this rct is to compare outcome with mcgrath vs macintosh laryngoscopes among patients undergoing thoracic surgery. the main questions it aims to answer are, 1. rate of successful intubation at first attempt and 2. time for intubation required with each device. participants are required to sign the informed consent for, they will be placed in two groups, group a: macintosh (dl) group b: mcgrath (vl) researchers will compare in group a: macintosh (dl) and group b: mcgrath (vl) the differences in rate of successful intubation at first attempt and time for intubation required with each device.


Eligibility criteria:
inclusion criteria: * age 18-65 years * american society of anaesthesiologists physical status (asa) i, ii, iii * elective thoracic surgery patients, requiring one lung ventilation. exclusion criteria: * patients requiring rapid sequence induction * patients with a structural problem in the airway on chest radiography * history of difficult intubation * planned tracheostomy \\ the presence of a tracheostomy * patients with a bmi \>35 kg\\m2. who at risk of regurgitation\\ aspiration * anticipated difficult airway (mallampati iv) * pre-existing sore throat or hoarseness, or recent respiratory infection (\<15 days)
a comparison between the effectiveness of vestibular and dual task on balance in diplegic children

Conditions: Diplegic Cerebral Palsy

Summary: the study is carried out to identify if there is any difference between the effectiveness of vestibular training and dual task training on balance in children with diplegic cerebral palsy. so in this study the sample will be divided into two equal groups, each group will recieve only one type of training ( vestibular training or dual task training ) the balance of the diplegic children will be assessed before and after using humac balance system and pediatric balance scale , the results will be compared between both groups and if there is one training is more effective than the other , it will be recommended most in the future treatment program.

a comparative experimental design was used. children participating in this study were assigned into two equal groups, thirty four children with diplegic cerebral palsy of both genders who have balance problems were selected to join this study with the following criteria: 1. all the children diagnosed as diplegic cerebral palsy. 2. their age are range from 5 to 10 years old. 3. the degree of spasticity is between grade 1 or 1+ according to modified ashworth scale (charalambous ,2013). 4. they are at level i or ii on gross motor function classification system . 5. all the children were able to follow verbal command and instructions. and children were excluded in the presence of the following: 1. children that suffer from epilepsy. 2. severe visual and auditory problems. 3. structural or fixed soft tissue deformities of lower extremities. 4. severe mental retardation. 5. botox injection in the lower extremity in the past 6 months.. all the children will be assigned in one of two groups ( vestibular training group and dual task group ) the training will be continue for definite period of time , and the balance abilities for the children in each group will be assessed before and after the treatment completely ended and the result will be compared to conclude which group benefit more and have a greater balance improvement and the treatment that causes a greater improvement will be more recommended in the future physical therapy plan for treatment of diplegic cerebral palsied children. the balance is assessed using humac balance system and pediatric balance scale .

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of diplegic cerebral palsy . 2. age range : from 5 to 10 years old. 3. the degree of spasticity is between grade 1 or 1+ according to modified ashworth scale (charalambous ,2013). 4. they are at level i or ii on gross motor function classification system . 5. all the children were able to follow verbal command and instructions. exclusion criteria: 1. children that suffer from epilepsy. 2. severe visual and auditory problems. 3. structural or fixed soft tissue deformities of lower extremities. 4. severe mental retardation. 5. botox injection in the lower extremity in the past 6 months
impact of intestinal virome on pediatric inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: over the last few years, dysbiosis has emerged as a possible trigger of gut inflammation in inflammatory bowel disease (ibd) and a promising therapeutic target. the complex diversity of microbiota was initially highlighted by the powerful new tools in genetics, including next-generation sequencing (ngs). ngs permitted to decipher the composition of bacterial intestinal communities, but also that of the gut virome. since then, the evidence of a dynamic instability of the enteric virome in ibd has grown considerably. ibd patients present an expansion of bacteriophages (caudovirales) associated with decreased bacterial diversity. moreover, gut virome richness seems to differ between crohn's disease (cd) and ulcerative colitis (uc) patients. these insights open the gate of new diagnostic, predictive, and therapeutic approaches. however, little is known about pediatric ibd gut virome in terms of variability and evolution under the influence of different treatments (exclusive enteral nutrition, immunosuppressive therapy and biologics). the aim of this study is to evaluate the gut family viral diversity and relative abundance of eukaryotes and prokaryotes in paediatric ibd patients


Eligibility criteria:
inclusion criteria: * age: 6-17 years * follow-up in pediatric gastroenterology for inflammatory bowel disease : * crohn's disease * hemorrhagic rectocolitis * introduction of anti-tnfa treatment in the pediatric gastroenterology day hospital of the "hôpital femme mère enfant" service in lyon * collection of the non-opposition of at least one of the holders of the parental authority present and the child in the medical file exclusion criteria: * refusal to participate in the study * antibiotherapy in the 4 weeks preceding the sampling * patient with ileostomy or colostomy. * patient who has undergone extensive bowel resection. * history of intestinal surgery (except appendectomy) * patient subject to a legal protection measure
covid-19 related lung ventilation and perfusion injury

Conditions: Covid-19; Asthma; Healthy

Summary: little is currently known about the immediate and long-term effect of covid-19 on lung ventilation (delivery of air to the lungs) and lung perfusion (delivery of blood to the lungs). some people who survive covid-19 may have lung ventilation and/or perfusion injury that persists following covid-19 recovery. this lung injury may be related to inflammation in the lung, breathlessness, exercise limitation and reduced quality of life. therefore, towards the goal of understanding the effects of covid-19 on lung health, the purpose of this study is to characterize and understand the clinical relevance of covid-19 related lung ventilation and perfusion injury and associated inflammatory status, ≤4 weeks and 6-months following covid-19 recovery in an asthmatic and healthy population. to do this, an asthmatic and healthy population who have, and have not, been previously diagnosed with covid-19 will be studied.


Eligibility criteria:
inclusion criteria: for all participants: * males and females ≥ 18 years of age * individuals able and willing to provide written informed consent * individuals able and willing to comply with the study protocol for participants with asthma: * individuals with physician confirmed asthma (12% bronchodilator reversibility or pc20 methacholine less than 8mg/ml) * individuals treated with inhaled corticosteroids, oral corticosteroids and/or anti-t2 biologics for participants who recently recovered from covid-19: * individuals previously diagnosed with covid-19 confirmed by floqswab test * individuals who recently (≤4-weeks) recovered from covid-19 exclusion criteria: for all participants: * males and females \< 18 years of age * individuals who are unable to read and/or understand english * individuals who are pregnant or breastfeeding * individuals who currently smoke or are an ex-smoker with ≥10 pack-year smoking history * individuals who in the opinion of the investigator, are mentally or legally incapacitated, preventing informed consent from being obtained * individuals who are unable to complete one or more study manoeuvres for participants with no history of lung disease: * individuals with a history of respiratory infection or disease for participants who have not been diagnosed with covid-19: * individuals who have previously had covid-19 confirmed by floqswab test

Keywords: covid-19 lung ventilation lung perfusion v/q spect lung health technegas
socket preservation after surgical extraction of impacted lower third molar

Conditions: Socket Preservation

Summary: the aim of this study will be to evaluate socket preservation using autogenous particulate dentin in combination with liquid platelet-rich fibrin versus bone allografts and collagen cone after surgical extraction of the horizontally impacted lower third molar

the aim of this study will be to evaluate socket preservation using autogenous particulate dentin in combination with liquid platelet-rich fibrin (sticky tooth) versus bone allografts and collagen cone after surgical extraction of the horizontally impacted lower third molar

Eligibility criteria:
inclusion criteria: 1. fresh extracted socket of horizontally impacted mandibular third molar 2. co-operative patients willing to complete the follow-up periods. 3. patients age from 18-35 years. 4. good oral hygiene. exclusion criteria: 1. any pathological condition at the site of surgery. 2. patients with systemic diseases that contra-indicate the surgical procedure such as uncontrolled diabetes mellitus, bleeding disorders, serious osseous disorders and mental disorders. 3. smokers . 4. pregnancy. -

Keywords: socket preservation dentine graft
cholesterol metabolites analysis in human thyroid and iodine resistance

Conditions: Thyroid Cancer

Summary: the study team previously shown that a cholesterol metabolite, dendrogenin a (dda) differentiates anaplastic thyroid cancer cell lines and that its mrna expression is diminished in human radioiodine refractory thyroid cancer samples. the team aim to quantify via mass spectrometry and immunohistochemistry dda and other cholesterol metabolites in thyroid cancer versus healthy thyroid tissue human samples.

retrospective study to analyze tissue samples of patients after thyroid surgery at claudius regaud institute toulouse, france, for thyroid cancer or thyroid aggressive lymphoma or benign thyroid pathology or other head\&neck pathology necessitating total thyroidectomy despite normal thyroid. analysis focused on cholesterol metabolites quatification by mass spectrometry in liquid and gas phase.

Eligibility criteria:
inclusion criteria: * patients who have undergone surgery at institut claudius regaud for thyroid or laryngeal cancer confirmed by histology. * patients who have consented before surgery, for the use of participants samples for future researches. exclusion criteria: * none

Keywords: cholesterol metabolites dendrogenin a (dda) 6-oxo-cholestane-3β,5α-diol (ocdo) 5,6 epoxy cholesterol thyroid cancer